TNYA Financials: Tenaya Therapeutics Inc AI Analysis

Home

Stock

TNYA

Financials

TNYA Financial

Tenaya Therapeutics Inc

$0.77

2.21%

$0.01

As of today:Mar 25, 10:50:40 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$0.7574

Open

$0.7792

Day's Range

$0.7627 - $0.804

52 week range

$0.36 - $2.35

Volume

1.0M

Avg.Volume

4.4M

Dividend yield

EPS (TTM)

-0.79

Market Cap

$165.4M

What is TNYA?

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 97 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

TNYA Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	24	24	29	33	31	18
Research & Development	68	68	86	98	94	54
Operating Expenses	93	93	115	131	125	72
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	-90	-90	-111	-124	-123	-72
Income Tax Expense	0	0	0	0	0	0
Net Income	-90	-90	-111	-124	-123	-72
Net Income Growth	-19%	-19%	-10%	1%	71%	89%
Shares Outstanding (Diluted)	175.29	152.97	84.82	73.78	44.82	17.73
Shares Change (YoY)	104%	80%	15%	65%	153%	-55%
EPS (Diluted)	-0.51	-0.59	-1.31	-1.68	-2.76	-4.1
EPS Growth	-60%	-55%	-22%	-39%	-33%	318%
Free Cash Flow	-68	-68	-91	-103	-125	-85
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-85	-85	-107	-123	-119	-70
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	8	8	8	8	6	2
EBIT	-93	-93	-115	-131	-125	-72
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Follow-Up Questions

What are Tenaya Therapeutics Inc's key financial statements?



According to the latest financial statement (Form-10K), Tenaya Therapeutics Inc has a total asset of $146, Net loss of $-90

What are the key financial ratios for TNYA?



Tenaya Therapeutics Inc's Current ratio is 6.34, has a Net margin is 0, sales per share of $0.

How is Tenaya Therapeutics Inc's revenue broken down by segment or geography?



Tenaya Therapeutics Inc largest revenue segment is China Development, at a revenue of 117,249,224 in the most earnings release.For geography, China is the primary market for Tenaya Therapeutics Inc, at a revenue of 117,249,224.

Is Tenaya Therapeutics Inc profitable?



no, according to the latest financial statements, Tenaya Therapeutics Inc has a net loss of $-90

Does Tenaya Therapeutics Inc have any liabilities?



yes, Tenaya Therapeutics Inc has liability of 23

How many outstanding shares for Tenaya Therapeutics Inc?



Tenaya Therapeutics Inc has a total outstanding shares of 216.76

Tenaya Therapeutics Inc (TNYA) Financial

TNYA Stock Price Chart